EFFECT OF AGE, AND SPLEEN AND TREATMENT STATUS ON MALE REPRODUCTIVE HORMONES AND SOME PHYSIOLOGICAL PARAMETER LEVELS IN PATIENTS WITH BETA-TALASSEMIA MAJOR

JAMELA JOUDA1*, RAJWAN ABDULJABBAR GHAZZAY2, WAFAA F AL-MOSAWY3

1Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq. 2Department of Pharmaceutical Chemistry, College of Pharmacy, Kerbala University, Kerbala, Iraq. 3Department of Pharmacology, College of Pharmacy, Kerbela University, Kerbala, Iraq.

Email: jamela.jouda@uomustansiriyah.idu.iq

Received: 17 January 2019, Revised and Accepted: 08 April 2019

ABSTRACT

Objective: This research was conducted to study the relationship between spleen status and chelation treatment status with the male reproductive hormones and some physiological parameter levels.

Methods: A total of 35 males with thalassemia major (TM) patients are recruited. Patients are grouped according to (1) their age into two groups; <18 years and ≥18 years, (2) their spleen status into two groups; splenectomy and non-splenectomy, and (3) their chelation treatment status into two groups; regulation and irregulation. Body mass index (BMI) was calculated and blood was collected from all patients just before blood transfusion session. Hb, ABO blood groups, ferritin, and hormone (luteinizing hormone [LH], follicle-stimulating hormone [FSH], testosterone, prolactin, and cortisol) levels were determined.

Results: The highest frequency of thalassemia was in Group O and the lowest was in AB. BMI was higher in TM patients aged ≥18 years, TM patients with splenectomy, and TM patient who take the treatment irregularly. TM patients aged ≥18 years have high level of LH, FSH, and testosterone. TM patients without splenectomy have higher FSH, prolactin, and testosterone. TM patients take the treatment regularly have significantly higher testosterone levels and non-significantly lower FSH level.

Conclusion: The levels of cortisol and prolactin hormones are not disturbed in TM patients and not associated with the rate of transfusion, but the level of Hb and ferritin lead to underweight in BMI and may lead to endocrine dysfunction, especially sexual hormones (FSH, LH, and testosterone). These BMI and sex hormones are related to age, spleen, and treatment status.

Keywords: Thalassemia major patients, Luteinizing hormone, Follicle-stimulating hormone, Testosterone, Chelation therapy, Splenectomy.

INTRODUCTION

β-Thalassemia is a serious genetic disorder that leads to a significant increase in both morbidity and acute and chronic mortality, especially in our developing countries, for at least the next few decades [1,2]. In the past, children with the disease rarely succeed to survival after adolescence [3]. In the late 1970s, quality of the patient's life was improved due to introduction of optimal red blood cell transfusions [4], but severe endocrine complications are developed in patients with multi-transfused due to iron overload [5]. The main reason for iron overload is increased iron absorption in the intestine due to it's requested by the body to produce new erythrocytes rather than the inefficient [6] or due to transfusions sometimes [7]. Iron overload caused many complications. One of these complications is hypogonadism in thalassemia patients [8,9].

Other complication of β-thalassemia includes hypersplenctomegaly. Splenomegaly is characterized by an increase in mechanical filtration of spleen and early destruction of blood components [10].

Splenectomy and almost daily subcutaneous chelation are the main therapies to reduce hemolysis resulting increase the lifespan of red cell, eliminate the need for regular transfusions, prevent the risk of iron overload [11], and normalize reproductive and sexual life [12].

Although thousands of people over the world have β-thalassemia and suffer from problems in the reproductive health, literature on these issues is rare, especially the relationship between the type of treatment and the sexual health. Hence, this research aimed to study the relationship between spleen status (splenectomy or not) and chelation treatment status (regulation or irregulation) with the male reproductive hormones (luteinizing hormone [LH], follicle-stimulating hormone [FSH], and testosterone) and some physiological parameter levels.

METHODS

A total of 35 Iraqi male with beta-thalassemia major (TM) patients are recruited from thalassemia center/Children's Teaching Hospital, Kerbala/Iraq, at the age of 14–29 years. All patients are blood transfusion dependent (20 ml packed RBCs/kg, at 2–3 weeks interval) to maintain a pretransfusion hemoglobin concentration above 8 g/l; also, all of them were on iron chelation therapy. A written informed patient consent was taken from all the volunteers in the study. The age, blood groups, spleen status, and treatment status are recorded from the profile of all patients. Patients are grouped according to:

1. Their age into two groups; <18 years and ≥18 years
2. Their spleen status into two groups; splenectomy and non-splenectomy
3. Their chelation treatment status into two groups; regulation and irregulation.

The body weights, by body balance, and height, by paper tape, of patients were measured and the body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared [13].
At morning and after taking consent, 5 ml blood was collected from all patients 2–3 weeks after the previous transfusion. Hb level was determined by hemoglobinometer. Then, the rest of blood was collected in a dry sterilized test tube. The blood samples were centrifuged for 5 min at 3000 rpm to obtain the serum that used to determine:

1. Male reproductive hormones
   a. FSH and LH levels by two-site immune enzymometric assay using the ST AIA-PACK FSH or LH, which is performed entirely in the AIA-PACK.
   b. Testosterone levels by competitive immunoenzymometric assay the ST AIA-PACK testosterone, which is performed entirely in the AIA-PACK.

2. Some physiological parameters
   a. Ferritin level by an enzyme-linked assay method using a kit supplied by Biomerieux (France), measured automatically with Minividas, Biomerieux (France).
   b. Cortisol level according to Tosoh Company.
   c. Prolactin by two-site immune enzymometric assay using the ST AIA-PACK PRL, which is performed entirely in the AIA-PACK.

Results are expressed as mean ± standard error or percentage. Data were analyzed by one sample test for percentages and by Student's t-test for other parameters comparison using Statview version 5.0. Differences were considered significant when p<0.05.

RESULTS

Table 1: The basic clinical manifestations of TM patients, in which there were only significant differences between the frequencies of blood groups, the highest frequency was Group O and the lowest was AB. The rest parameters showed non-significant differences.

<table>
<thead>
<tr>
<th>Character</th>
<th>Sample value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Range</td>
<td>15–30</td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>20.1±4.17</td>
<td>0.126</td>
</tr>
<tr>
<td>&lt;18 years n (%)</td>
<td>14 (40)</td>
<td></td>
</tr>
<tr>
<td>≥18 years n (%)</td>
<td>21 (60)</td>
<td></td>
</tr>
<tr>
<td>Blood groups n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>9 (26)</td>
<td>0.043</td>
</tr>
<tr>
<td>B</td>
<td>9 (26)</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>3 (6)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>14 (42)</td>
<td></td>
</tr>
<tr>
<td>Spleen status n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenectomize</td>
<td>21 (60)</td>
<td>0.126</td>
</tr>
<tr>
<td>Non-splenectomize</td>
<td>14 (40)</td>
<td></td>
</tr>
<tr>
<td>Treatment status n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular</td>
<td>14 (40)</td>
<td>0.126</td>
</tr>
<tr>
<td>Irregular</td>
<td>21 (60)</td>
<td></td>
</tr>
</tbody>
</table>

SD: Standard deviation

The result of estimated parameters in all groups is showed in Table 2; it showed that TM patients aged <18 years have significant higher Hb value than those who aged ≥18 years while TM patients aged ≥18 years have significant higher BMI value. However, ferritin showed non-significant difference between the two groups of TM patients.

According to spleen status, TM patients with splenectomy have higher BMI value than those with non-splenectomy, while the rest parameters showed non-significant differences.

Discrepancies were considered significant when p<0.05. The result of estimated parameters in all groups is showed in Table 2; it showed that TM patients aged <18 years have significant higher Hb value than those who aged ≥18 years while TM patients aged ≥18 years have significant higher BMI value. However, ferritin showed non-significant difference between the two groups of TM patients.

Finally, according to chelation treatment status, TM patients who take the treatment irregularly have significant higher BMI and ferritin values compared to who take the treatment regularly. However, the rest parameters showed non-significant differences.

Table 2: Estimation of parameter’s level in both groups of TM patients according to age, and spleen and treatment status

<table>
<thead>
<tr>
<th>Characters</th>
<th>Hb (g/dl)</th>
<th>BMI (kg/m²)</th>
<th>Ferritin (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;18 years</td>
<td>9.3±0.3*</td>
<td>17.7±0.5</td>
<td>2788.2±421.4</td>
</tr>
<tr>
<td>≥18 years</td>
<td>8.6±0.2</td>
<td>19.5±0.5*</td>
<td>3265.9±442.03</td>
</tr>
<tr>
<td>p value</td>
<td>0.045</td>
<td>0.031</td>
<td>0.51</td>
</tr>
<tr>
<td>Spleen status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenectomize</td>
<td>8.97±0.24</td>
<td>19.8±0.43*</td>
<td>3125.0±493.8</td>
</tr>
<tr>
<td>Non-splenectomize</td>
<td>8.81±0.23</td>
<td>17.9±0.64</td>
<td>3427.0±466.3</td>
</tr>
<tr>
<td>p value</td>
<td>0.721</td>
<td>0.0165</td>
<td>0.68</td>
</tr>
<tr>
<td>Treatment status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular</td>
<td>8.87±0.31</td>
<td>17.9±0.64</td>
<td>2002.3±394.9</td>
</tr>
<tr>
<td>Irregular</td>
<td>8.95±0.21</td>
<td>19.9±0.44*</td>
<td>3604.7±436.3*</td>
</tr>
<tr>
<td>p value</td>
<td>0.840</td>
<td>0.0245</td>
<td>0.0238</td>
</tr>
</tbody>
</table>

*Significant differences between two groups.
system status, and nutrition [28]. Fung et al. [29] reported that the underweight status increased among childhood and adolescence with thalassemia. The reasons can be the presence of hypogonadism, undernutrition [30-32], and the side effects of chelation treatment, which used to decrease iron level in these patients [33]. In our results, BMI was higher in TM patients aged ≥18 years, in TM patients who take the chelation treatment regularly and TM patients with splenectomy compared to TM patients aged <18 years, TM patients who take the chelation treatment regularly, and TM patients with non-splenectomy, respectively. TM patients who take the treatment irregularly have also significant higher ferritin values compared to who take the treatment regularly.

In the classic knowledge, iron accumulated in the pituitary gland of thalassemia patients results a cytotoxic effect. These cytotoxic effects result to hyporesponsiveness of pituitary gland to GnRH and lead to hypergonadotrophic hypogonadism [34], which can appear as low estradiol or testosterone with LH and low FSH [8]. Iron overload is also exist in reproductive glands which lead to undifferentiate the sperm tubes, decrease number of Leydig cells, and interstitial fibrosis in varying degrees [35,36]. It is clear that during childhood, the levels of testosterone, LH, and FSH remain very low until the onset of puberty [8]. These evidences can explain the high level of LH, FSH, and testosterone in TM patients aged ≥18 years compared to TM patients aged <18 years.

Glandular insufficiency does not respond to late chelation treatment of the disease [37], but prepuberty chelation therapy has helped patients get normal sexual maturity in some studies [8]. In contrast, another study reported that there was no difference in the frequency of pluripotent maturity when treatment began with iron ingestion at the age of 10 or earlier [18]. However, with modern drugs, iron deficiency glands may be reversible with iron intensive chelation systems [8]. In our results, TM patients take the chelation treatment regularly have significantly higher testosterone levels and non-significantly lower FSH level compared to who take treatment irregularly.

The hypothalamic-pituitary-gonadal axis is strongly involved in regulating the immune system. There is a link between the gonads and the spleen. Han et al [38] reported that the deprivation of testosterone by surgical castration increases GnRH and many immune cytokine expressions in the spleen. Immune castration increases the production of GnRH in the spleen by eliminating the effects of the inhibitory reactions of testosterone, thereby improving the immune markers of the immune cytokines of the spleen and serum [38-40]. This can explain the high level of testosterone and prolactin in splenectomize thalassemic patients in this study. It seems that hyperprolactinemia does not participate in the cause of hypergonadotrophic hypogonadism in thalassemia patients [30]. Plasma levels of prolactin were within the normal range of all male and female hypogonadal patients [32]. In this study, there were no differences in the prolactin levels according to age and treatment status.

The usual tests of adrenal function in patients with thalassemia have shown little weakness in function but have always worked at maximum rate to produce normal levels of cortisol spread [33]. Landon et al. [41] showed a very large suppression of function in the physiological range with a normal function reserve using the more gradual physiological cortical stimulation test [34]. This could explain why there were no differences in thalamic patients according to age, and treatment and spleen status.

**CONCLUSION**

The levels of cortisol and prolactin hormones are not disturbed in TM patients and not associated with the rate of transfusion, but the level of Hb and ferritin leads to underweight in BMI and may lead to endocrine dysfunction, especially sexual hormones (FSH, LH, and testosterone). These BMI and sex hormones are related to age, and spleen and treatment status.

**AUTHORS’ CONTRIBUTIONS**

All authors contributed to the design and implementation of the research, to the analysis of the results, and to the writing of the manuscript.

**CONFLICTS OF INTEREST**

There are no conflicts of interest of any sort.

**REFERENCES**


